[Skip to Content]
[Skip to Content Landing]
December 6, 2006

Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer

Author Affiliations

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2006;296(21):2555-2560. doi:10.1001/jama.296.21.2558-c

To the Editor: The immunomodulatory drugs thalidomide and lenalidomide recently received US Food and Drug Administration approval for the treatment of multiple myeloma.1-4 Venous thromboembolism (VTE) is a potentially serious complication associated with their use.5-8 We conducted a systematic review of thromboembolism occurring with immunomodulatory drug treatment of cancer.